DRUG-CLASS OVERVIEW:@0.982174:0.513429:0.982174:0.311367:0.954164:0.311367:0.954164:0.513429:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.233372:0.041064:0.000000:0.000000:0.019473
207:@0.945393:0.038601:0.984904:0.038601:0.984904:0.019004:0.945393:0.019004:0.013170:0.013170:0.013170
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
71. :@0.084848:0.078073:0.113276:0.078073:0.113276:0.064068:0.084848:0.064068:0.009476:0.009476:0.004738:0.004738
 Pharmacia.  Depo-Provera  (medroxypro-:@0.131885:0.078073:0.475760:0.078073:0.475760:0.064068:0.131885:0.064068:0.000000:0.010126:0.010434:0.011682:0.005617:0.016044:0.011682:0.011067:0.003421:0.011682:0.004738:0.004738:0.004610:0.012726:0.011118:0.011665:0.011203:0.005679:0.010126:0.005075:0.011203:0.009476:0.011118:0.005148:0.011682:0.004738:0.004601:0.006312:0.016044:0.011118:0.011716:0.005080:0.011203:0.008210:0.009168:0.011665:0.005078:0.011203:0.005679
gesterone acetate) injection, suspension.:@0.131886:0.092373:0.475767:0.092373:0.475767:0.078367:0.131886:0.078367:0.011511:0.011118:0.006636:0.005798:0.011118:0.005080:0.011203:0.010434:0.011118:0.005617:0.011682:0.011067:0.011118:0.005798:0.011682:0.005798:0.011118:0.006312:0.005627:0.003421:0.010434:0.003472:0.011118:0.011067:0.005798:0.003421:0.011203:0.010434:0.004738:0.005619:0.006636:0.010399:0.006636:0.011665:0.011118:0.010434:0.006636:0.003421:0.011203:0.010434:0.004738
Vol. 2013  (U.S. National Library of Medi-:@0.131885:0.106672:0.475753:0.106672:0.475753:0.092666:0.131885:0.092666:0.010281:0.011203:0.003421:0.004738:0.008689:0.009476:0.009476:0.009476:0.009476:0.004738:0.003968:0.006312:0.011203:0.004738:0.008518:0.004738:0.008689:0.012657:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.008689:0.007902:0.003421:0.011665:0.005148:0.011682:0.005148:0.009168:0.008689:0.011203:0.005371:0.008689:0.015719:0.011118:0.011716:0.003421:0.005679
cine, published online, 2006).:@0.131885:0.120971:0.371073:0.120971:0.371073:0.106966:0.131885:0.106966:0.011067:0.003421:0.010434:0.011118:0.004738:0.004738:0.011665:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
72.:@0.084848:0.135270:0.108538:0.135270:0.108538:0.121265:0.084848:0.121265:0.009476:0.009476:0.004738
  Jakobsen JN, Herrstedt  J. Prevention of:@0.131885:0.135270:0.475779:0.135270:0.475779:0.121265:0.131885:0.121265:0.004738:-0.004738:0.008244:0.011682:0.008586:0.011203:0.011665:0.006636:0.011118:0.010434:0.009356:0.008244:0.012657:0.004738:0.009356:0.011682:0.011118:0.005148:0.005148:0.006636:0.005798:0.011118:0.011716:0.005798:0.004738:0.004601:0.008244:0.004738:0.009356:0.010126:0.005073:0.011118:0.009476:0.011118:0.010434:0.005798:0.003421:0.011203:0.010434:0.009356:0.011203:0.005371
chemotherapy-induced:@0.131885:0.149570:0.332314:0.149570:0.332314:0.135564:0.131885:0.135564:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.005679:0.003421:0.010434:0.011716:0.010399:0.011067:0.011118:0.011716
nausea:@0.356137:0.149570:0.418089:0.149570:0.418089:0.135564:0.356137:0.135564:0.010434:0.011682:0.010399:0.006636:0.011118:0.011682
and:@0.441933:0.149570:0.475765:0.149570:0.475765:0.135564:0.441933:0.135564:0.011682:0.010434:0.011716
vomiting in elderly cancer patients. :@0.131885:0.163869:0.436249:0.163869:0.436249:0.149864:0.131885:0.149864:0.009476:0.011203:0.016044:0.003421:0.005798:0.003421:0.010434:0.011511:0.006883:0.003421:0.010434:0.006893:0.011118:0.003421:0.011716:0.011118:0.005148:0.003421:0.009168:0.006893:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.006878:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.004738:0.004738
Criti-:@0.438378:0.163869:0.475751:0.163869:0.475751:0.149864:0.438378:0.149864:0.013906:0.005148:0.003421:0.005798:0.003421:0.005679
cal Reviews in Oncology/Hematology.:@0.131885:0.178168:0.475751:0.178168:0.475751:0.164163:0.131885:0.164163:0.011067:0.011682:0.003421:0.013187:0.010382:0.011118:0.009476:0.003421:0.011118:0.014214:0.006636:0.013187:0.003421:0.010434:0.013187:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.007475:0.011682:0.011118:0.016044:0.011682:0.005798:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738
2009; 71:214-221.:@0.131885:0.192467:0.270225:0.192467:0.270225:0.178462:0.131885:0.178462:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
73. :@0.084848:0.207061:0.113276:0.207061:0.113276:0.193055:0.084848:0.193055:0.009479:0.009479:0.004731:1.065199
  Amgen. Neupogen  (filgrastim). 1-25. (FDA,:@0.131885:0.207061:0.475752:0.207073:0.475752:0.193067:0.131885:0.193055:0.004738:-0.004738:0.012452:0.015839:0.011306:0.010913:0.010228:0.004533:0.003554:0.012452:0.010913:0.010194:0.011460:0.010998:0.011306:0.010913:0.010434:0.007095:0.003554:0.006106:0.004062:0.004062:0.003216:0.011306:0.004943:0.011477:0.006431:0.005593:0.003216:0.015839:0.006106:0.004533:0.003554:0.009271:0.005473:0.009271:0.009271:0.004533:0.003554:0.006106:0.008090:0.012520:0.012452:0.702705
®:@0.289144:0.202078:0.296593:0.202078:0.296593:0.193913:0.289144:0.193913:0.007449
published online, 2002).:@0.131879:0.221666:0.325552:0.221666:0.325552:0.207661:0.131879:0.207661:0.011665:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
74. :@0.084842:0.236259:0.113269:0.236259:0.113269:0.222254:0.084842:0.222254:0.009476:0.009476:0.004738:0.004738
  Amgen.  Neupogen   (filgrastim)  Informa-:@0.131879:0.236259:0.475757:0.236262:0.475757:0.222257:0.131879:0.222254:0.004738:-0.004738:0.012657:0.016044:0.011511:0.011118:0.010434:0.004738:0.004738:0.003691:0.012657:0.011118:0.010399:0.011665:0.011203:0.011511:0.011118:0.010434:0.007441:0.004738:0.003705:0.006312:0.004165:0.004165:0.003421:0.011511:0.005148:0.011682:0.006636:0.005798:0.003421:0.016044:0.006312:0.004738:0.003712:0.003866:0.010434:0.005371:0.011203:0.005615:0.016044:0.011682:0.661184
®:@0.296906:0.231267:0.304355:0.231267:0.304355:0.223102:0.296906:0.223102:0.007449
tion for patients and caregivers. 10th Ed.:@0.131893:0.250855:0.475759:0.250855:0.475759:0.236850:0.131893:0.236850:0.005798:0.003421:0.011203:0.010434:0.006517:0.005371:0.011203:0.005148:0.006517:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.006517:0.011682:0.010434:0.011716:0.006517:0.011067:0.011682:0.005080:0.011118:0.011511:0.003421:0.009476:0.011118:0.005148:0.006636:0.004738:0.006517:0.009476:0.009476:0.005798:0.010434:0.006517:0.009168:0.011716:0.004738
1-14. (Amgen, published online, 2013).:@0.131893:0.265448:0.446699:0.265448:0.446699:0.251443:0.131893:0.251443:0.009476:0.005679:0.009476:0.009476:0.004738:0.004738:0.006312:0.012657:0.016044:0.011511:0.011118:0.010434:0.004738:0.004738:0.011665:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
75. :@0.084856:0.280042:0.113283:0.280042:0.113283:0.266036:0.084856:0.266036:0.009476:0.009476:0.004738:0.004738
  Amgen. Nplate  (romiplostim), for subcu-:@0.131893:0.280042:0.475760:0.280046:0.475760:0.266040:0.131893:0.266036:0.004738:-0.004738:0.012657:0.016044:0.011511:0.011118:0.010434:0.004738:0.006168:0.012657:0.011665:0.003421:0.011682:0.005798:0.011118:0.007442:0.006182:0.006312:0.005080:0.011203:0.016044:0.003421:0.011665:0.003421:0.011203:0.006636:0.005798:0.003421:0.016044:0.006312:0.004738:0.006192:0.005371:0.011203:0.005148:0.006175:0.006636:0.010399:0.011665:0.011067:0.010399:0.597495
®:@0.260896:0.275051:0.268345:0.275051:0.268345:0.266886:0.260896:0.266886:0.007449
taneous injection. 1-4 (Amgen, published:@0.131887:0.294639:0.475752:0.294639:0.475752:0.280634:0.131887:0.280634:0.005798:0.011682:0.010434:0.011118:0.011203:0.010399:0.006636:0.005889:0.003421:0.010434:0.003472:0.011118:0.011067:0.005798:0.003421:0.011203:0.010434:0.004738:0.005892:0.009476:0.005679:0.009476:0.005901:0.006312:0.012657:0.016044:0.011511:0.011118:0.010434:0.004738:0.005886:0.011665:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716
online 2012).:@0.131887:0.309232:0.235608:0.309232:0.235608:0.295227:0.131887:0.295227:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
76. :@0.084850:0.323825:0.113278:0.323825:0.113278:0.309820:0.084850:0.309820:0.009476:0.009476:0.004738:0.004738
  Janssen-Cilag. EPREX  intravenous & sub-:@0.131887:0.323825:0.475765:0.323830:0.475765:0.309824:0.131887:0.309820:0.004738:-0.004738:0.008244:0.011682:0.010434:0.006636:0.006636:0.011118:0.010434:0.005679:0.013906:0.003421:0.003421:0.011682:0.011511:0.004738:0.006140:0.009168:0.010126:0.010382:0.009168:0.010417:0.007446:0.006140:0.003421:0.010434:0.005798:0.005148:0.011682:0.009476:0.011118:0.010434:0.011203:0.010399:0.006636:0.006130:0.012948:0.006140:0.006636:0.010399:0.011665:0.533804
®:@0.306827:0.318835:0.314276:0.318835:0.314276:0.310670:0.306827:0.310670:0.007449
cutaneous injection product information.:@0.131892:0.338423:0.475772:0.338423:0.475772:0.324418:0.131892:0.324418:0.011067:0.010399:0.005798:0.011682:0.010434:0.011118:0.011203:0.010399:0.006636:0.006158:0.003421:0.010434:0.003472:0.011118:0.011067:0.005798:0.003421:0.011203:0.010434:0.006161:0.011665:0.005080:0.011203:0.011716:0.010399:0.011067:0.005798:0.006158:0.003421:0.010434:0.005371:0.011203:0.005620:0.016044:0.011682:0.005798:0.003421:0.011203:0.010434:0.004738
1-16 (Janssen, published online, 2012).:@0.131892:0.353016:0.445381:0.353016:0.445381:0.339011:0.131892:0.339011:0.009476:0.005679:0.009476:0.009476:0.004738:0.006312:0.008244:0.011682:0.010434:0.006636:0.006636:0.011118:0.010434:0.004738:0.004738:0.011665:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
77.:@0.084855:0.367609:0.108545:0.367609:0.108545:0.353604:0.084855:0.353604:0.009476:0.009476:0.004738
  Hoffman-La.  Roche.  Recormon  Epoetin:@0.131892:0.367609:0.475764:0.367613:0.475764:0.353608:0.131892:0.353604:0.004738:-0.004738:0.011682:0.011203:0.005422:0.005371:0.016044:0.011682:0.010434:0.005679:0.007902:0.011682:0.004738:0.004738:0.003857:0.010382:0.011203:0.011067:0.010434:0.011118:0.004738:0.004738:0.003850:0.010382:0.011118:0.011067:0.011203:0.005614:0.016044:0.011203:0.010434:0.007432:0.008603:0.009168:0.011665:0.011203:0.011118:0.005798:0.003421:0.474875
®:@0.396904:0.362619:0.404353:0.362619:0.404353:0.354454:0.396904:0.354454:0.007449
beta. (Hoffman-La Roche, published on-:@0.131881:0.382206:0.475766:0.382206:0.475766:0.368201:0.131881:0.368201:0.011665:0.011118:0.005798:0.011682:0.004738:0.007184:0.006312:0.011682:0.011203:0.005422:0.005371:0.016044:0.011682:0.010434:0.005679:0.007902:0.011682:0.007184:0.010382:0.011203:0.011067:0.010434:0.011118:0.004738:0.007174:0.011665:0.010399:0.011665:0.003421:0.003421:0.006648:0.010434:0.011118:0.011716:0.007184:0.011203:0.010434:0.005679
line, 2007).:@0.131881:0.396800:0.218703:0.396800:0.218703:0.382794:0.131881:0.382794:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
78.:@0.084844:0.411393:0.108534:0.411393:0.108534:0.397388:0.084844:0.397388:0.009476:0.009476:0.004738
 Trescot AM, Datta S, Lee M, :@0.131881:0.411393:0.369254:0.411393:0.369254:0.397388:0.131881:0.397388:0.000000:0.006773:0.005078:0.011118:0.006636:0.011067:0.011203:0.005798:0.006058:0.012657:0.015719:0.004738:0.006057:0.012726:0.011682:0.005798:0.005798:0.011682:0.006072:0.008518:0.004738:0.006062:0.007902:0.011118:0.011118:0.006060:0.015719:0.004738:0.004738
et al:@0.370572:0.411393:0.408652:0.411393:0.408652:0.397388:0.370572:0.397388:0.011118:0.005798:0.006060:0.011682:0.003421
. Opioid:@0.408652:0.411393:0.475742:0.411393:0.475742:0.397388:0.408652:0.397388:0.004738:0.006062:0.014864:0.011665:0.003421:0.011203:0.003421:0.011716
pharmacology. :@0.131881:0.425986:0.266060:0.425986:0.266060:0.411981:0.131881:0.411981:0.011665:0.010434:0.011682:0.005622:0.016044:0.011682:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738:0.004738
Pain  Physician Journal.:@0.273693:0.425986:0.475771:0.425986:0.475771:0.411981:0.273693:0.411981:0.010126:0.011682:0.003421:0.010434:0.004738:0.007635:0.010126:0.010434:0.009168:0.006636:0.003421:0.011067:0.003421:0.011682:0.010434:0.012384:0.008244:0.011203:0.010399:0.005148:0.010434:0.011682:0.003421:0.004738
2008;11:S133-S153.:@0.131898:0.440579:0.282536:0.440579:0.282536:0.426574:0.131898:0.426574:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.008518:0.009476:0.009476:0.009476:0.005679:0.008518:0.009476:0.009476:0.009476:0.004738
79.:@0.084861:0.455173:0.108551:0.455173:0.108551:0.441167:0.084861:0.441167:0.009476:0.009476:0.004738
 Dahan A, van Dorp E, Smith T, :@0.131898:0.455173:0.387921:0.455173:0.387921:0.441167:0.131898:0.441167:0.000000:0.012726:0.011682:0.010434:0.011682:0.010434:0.006038:0.012657:0.004738:0.006021:0.009476:0.011682:0.010434:0.006038:0.012726:0.011203:0.005148:0.011665:0.006029:0.009168:0.004738:0.006038:0.008518:0.016044:0.003421:0.005798:0.010434:0.006038:0.005538:0.004738:0.004738
et al.:@0.389221:0.455173:0.432008:0.455173:0.432008:0.441167:0.389221:0.441167:0.011118:0.005798:0.006029:0.011682:0.003421:0.004738
 Mor-:@0.432008:0.455173:0.475795:0.455173:0.475795:0.441167:0.432008:0.441167:0.006038:0.015719:0.011203:0.005148:0.005679
phine-6-glucuronide (M6G) for postoper-:@0.131898:0.469766:0.475764:0.469766:0.475764:0.455761:0.131898:0.455761:0.011665:0.010434:0.003421:0.010434:0.011118:0.005679:0.009476:0.005679:0.011511:0.003421:0.010399:0.011067:0.010399:0.005078:0.011203:0.010434:0.003421:0.011716:0.011118:0.007209:0.006312:0.015719:0.009476:0.014915:0.006312:0.007218:0.005371:0.011203:0.005148:0.007204:0.011665:0.011203:0.006636:0.005798:0.011203:0.011665:0.011118:0.005138:0.005679
ative pain relief. :@0.131898:0.484359:0.267122:0.484359:0.267122:0.470354:0.131898:0.470354:0.011682:0.005798:0.003421:0.009476:0.011118:0.003763:0.011665:0.011682:0.003421:0.010434:0.003763:0.005077:0.011118:0.003421:0.003421:0.011118:0.005371:0.004738:0.004738
European Journal of Pain.:@0.266147:0.484359:0.475751:0.484359:0.475751:0.470354:0.266147:0.470354:0.009168:0.010399:0.005148:0.011203:0.011665:0.011118:0.011682:0.010434:0.003763:0.008244:0.011203:0.010399:0.005148:0.010434:0.011672:0.003421:0.003763:0.011203:0.005371:0.003763:0.010126:0.011682:0.003421:0.010434:0.004738
2008;12:403-411.:@0.131898:0.498952:0.265500:0.498952:0.265500:0.484947:0.131898:0.484947:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
80.:@0.084861:0.513546:0.108551:0.513546:0.108551:0.499540:0.084861:0.499540:0.009476:0.009476:0.004738
  Raffa RB. Pharmacology of oral combina-:@0.131898:0.513546:0.475776:0.513546:0.475776:0.499540:0.131898:0.499540:0.004738:-0.004738:0.010382:0.011682:0.005422:0.005371:0.011682:0.004413:0.010382:0.009818:0.004738:0.004404:0.010126:0.010434:0.011682:0.005615:0.016044:0.011682:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004403:0.011203:0.005371:0.004399:0.011203:0.005148:0.011682:0.003421:0.004401:0.011067:0.011203:0.016044:0.011665:0.003421:0.010434:0.011682:0.005679
tion analgesics: rational therapy for pain.:@0.131898:0.528139:0.475778:0.528139:0.475778:0.514134:0.131898:0.514134:0.005798:0.003421:0.011203:0.010434:0.005838:0.011682:0.010434:0.011682:0.003421:0.011511:0.011118:0.006636:0.003421:0.011067:0.006636:0.004738:0.005850:0.005148:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.005850:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.005839:0.005371:0.011203:0.005148:0.005834:0.011665:0.011682:0.003421:0.010434:0.004738
Journal of Clinical Pharmacy and Thera-:@0.131898:0.542732:0.475764:0.542732:0.475764:0.528727:0.131898:0.528727:0.008244:0.011203:0.010399:0.005148:0.010434:0.011682:0.003421:0.007088:0.011203:0.005371:0.007098:0.013906:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.007098:0.010126:0.010434:0.011682:0.005148:0.016044:0.011682:0.011067:0.009168:0.007090:0.011682:0.010434:0.011716:0.007098:0.007286:0.010434:0.011118:0.005148:0.011667:0.005679
peutics.:@0.131898:0.557325:0.196741:0.557325:0.196741:0.543320:0.131898:0.543320:0.011665:0.011118:0.010399:0.005798:0.003421:0.011067:0.006636:0.004738
 2001;26:257-264.:@0.196741:0.557325:0.335081:0.557325:0.335081:0.543320:0.196741:0.543320:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
81.:@0.084861:0.571919:0.108551:0.571919:0.108551:0.557913:0.084861:0.557913:0.009476:0.009476:0.004738
  Ong CKS, Seymour RA, Lirk P, :@0.131898:0.571919:0.378526:0.571919:0.378526:0.557913:0.131898:0.557913:0.004738:-0.004738:0.014864:0.010434:0.011511:0.006123:0.013906:0.010109:0.008518:0.004738:0.006125:0.008518:0.011118:0.009168:0.016044:0.011203:0.010399:0.005148:0.006122:0.010382:0.012657:0.004738:0.006123:0.007902:0.003421:0.005148:0.008586:0.006128:0.008017:0.004738:0.004738
et al.:@0.379928:0.571919:0.422813:0.571919:0.422813:0.557913:0.379928:0.557913:0.011118:0.005798:0.006127:0.011682:0.003421:0.004738
 Com-:@0.422813:0.571919:0.475774:0.571919:0.475774:0.557913:0.422813:0.557913:0.006130:0.013906:0.011203:0.016044:0.005679
bining paracetamol (acetaminophen):@0.131898:0.586512:0.475781:0.586512:0.475781:0.572507:0.131898:0.572507:0.011665:0.003421:0.010434:0.003421:0.010434:0.011511:0.016882:0.011665:0.011682:0.005148:0.011682:0.011067:0.011118:0.005798:0.011682:0.016044:0.011203:0.003421:0.016882:0.006312:0.011682:0.011067:0.011118:0.005798:0.011682:0.016044:0.003421:0.010434:0.011203:0.011665:0.010434:0.011118:0.010434:0.006312
with nonsteroidal antiinflammatory drugs::@0.131898:0.601105:0.475776:0.601105:0.475776:0.587100:0.131898:0.587100:0.014214:0.003421:0.005798:0.010434:0.005822:0.010434:0.011203:0.010425:0.006636:0.005798:0.011118:0.005078:0.011203:0.003421:0.011716:0.011682:0.003421:0.005827:0.011682:0.010434:0.005798:0.003421:0.003421:0.010434:0.004148:0.004148:0.011682:0.016044:0.016044:0.011682:0.005798:0.011203:0.005148:0.009168:0.005819:0.011716:0.005148:0.010399:0.011511:0.006636:0.004738
a qualitative systematic review of analge-:@0.131898:0.615698:0.475773:0.615698:0.475773:0.601693:0.131898:0.601693:0.011682:0.004079:0.011665:0.010399:0.011682:0.003421:0.003421:0.005798:0.011682:0.005798:0.003421:0.009476:0.011118:0.004088:0.006636:0.009168:0.006636:0.005798:0.011118:0.016044:0.011682:0.005798:0.003421:0.011067:0.004088:0.005078:0.011118:0.009476:0.003421:0.011118:0.014214:0.004088:0.011203:0.005371:0.004073:0.011682:0.010434:0.011682:0.003421:0.011511:0.011118:0.005679
sic  efficacy  for  acute  postoperative:@0.131898:0.630292:0.475781:0.630292:0.475781:0.616286:0.131898:0.616286:0.006636:0.003421:0.011067:0.004738:0.012077:0.011118:0.005371:0.004165:0.004165:0.011067:0.011682:0.011067:0.009168:0.004738:0.012074:0.005371:0.011203:0.005148:0.004738:0.012067:0.011682:0.011067:0.010399:0.005798:0.011118:0.004738:0.012067:0.011665:0.011203:0.006636:0.005798:0.011203:0.011665:0.011118:0.005148:0.011682:0.005798:0.003421:0.009476:0.011118
pain. :@0.131898:0.644885:0.178576:0.644885:0.178576:0.630880:0.131898:0.630880:0.011665:0.011682:0.003421:0.010434:0.004738:0.004738
Anesthesia & Analgesia.:@0.182818:0.644885:0.390961:0.644885:0.390961:0.630880:0.182818:0.630880:0.012657:0.010434:0.011118:0.006636:0.005798:0.010434:0.011118:0.006636:0.003421:0.011682:0.008980:0.012948:0.008980:0.012657:0.010434:0.011682:0.003421:0.011511:0.011118:0.006636:0.003421:0.011682:0.004738
 2010;110::@0.390961:0.644885:0.475747:0.644885:0.475747:0.630880:0.390961:0.630880:0.008980:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738
1170-1179.:@0.131898:0.659478:0.218121:0.659478:0.218121:0.645473:0.131898:0.645473:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
82.:@0.084861:0.674071:0.108551:0.674071:0.108551:0.660066:0.084861:0.660066:0.009476:0.009476:0.004738
  Eisenberg E, River Y, Shifrin A, :@0.131898:0.674071:0.377031:0.674071:0.377031:0.660066:0.131898:0.660066:0.004738:-0.004738:0.009168:0.003421:0.006636:0.011118:0.010434:0.011665:0.011118:0.005166:0.011511:0.005872:0.009168:0.004738:0.005875:0.010382:0.003421:0.009476:0.011118:0.005148:0.005875:0.008460:0.004738:0.005872:0.008518:0.010434:0.003421:0.005371:0.005148:0.003421:0.010434:0.005874:0.012657:0.004738:0.004738
et al.:@0.378167:0.674071:0.420794:0.674071:0.420794:0.660066:0.378167:0.660066:0.011118:0.005798:0.005870:0.011682:0.003421:0.004738
 Antie-:@0.420794:0.674071:0.475776:0.674071:0.475776:0.660066:0.420794:0.660066:0.005875:0.012657:0.010434:0.005798:0.003421:0.011118:0.005679
pileptic drugs in the treatment of neuro-:@0.131898:0.688665:0.475774:0.688665:0.475774:0.674659:0.131898:0.674659:0.011665:0.003421:0.003421:0.011118:0.011665:0.005798:0.003421:0.011067:0.007064:0.011716:0.005148:0.010399:0.011511:0.006636:0.007056:0.003421:0.010434:0.007064:0.005798:0.010434:0.011118:0.007052:0.005798:0.005075:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.007050:0.011203:0.005371:0.007052:0.010434:0.011118:0.010399:0.005073:0.011203:0.005679
pathic pain. :@0.131898:0.703258:0.237381:0.703258:0.237381:0.689252:0.131898:0.689252:0.011665:0.011682:0.005798:0.010434:0.003421:0.011067:0.004738:0.011665:0.011682:0.003421:0.010434:0.004738:0.004738
Drugs. :@0.237381:0.703258:0.293278:0.703258:0.293278:0.689252:0.237381:0.689252:0.012726:0.005148:0.010399:0.011511:0.006636:0.004738:0.004738
2007;67:1265-89.:@0.293278:0.703258:0.426880:0.703258:0.426880:0.689252:0.293278:0.689252:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
83. :@0.084861:0.717851:0.113289:0.717851:0.113289:0.703846:0.084861:0.703846:0.009479:0.009479:0.004731:0.004738
 Bennett MI. Effectiveness of antiepileptic:@0.131898:0.717851:0.475798:0.717851:0.475798:0.703846:0.131898:0.703846:0.000000:0.010126:0.011426:0.010742:0.010742:0.011426:0.006106:0.006106:0.004071:0.016027:0.004173:0.005046:0.004071:0.009476:0.005730:0.005679:0.011426:0.011374:0.006106:0.003729:0.009784:0.011426:0.010742:0.011426:0.006944:0.006944:0.004071:0.011511:0.005679:0.004071:0.011990:0.010742:0.006106:0.003729:0.011426:0.011973:0.003729:0.003729:0.011426:0.011973:0.006106:0.003729:0.011067
or antidepressant drugs when added:@0.131898:0.732444:0.475795:0.732444:0.475795:0.718439:0.131898:0.718439:0.011511:0.005456:0.011460:0.011990:0.010742:0.006106:0.003729:0.012024:0.011426:0.011973:0.005384:0.011426:0.006944:0.006944:0.011990:0.010742:0.006106:0.011460:0.012024:0.005456:0.010707:0.011819:0.006944:0.011460:0.014522:0.010742:0.011426:0.010742:0.011460:0.011990:0.012024:0.012024:0.011426:0.011716
to  opioids  for  cancer  pain:  systematic:@0.131898:0.747037:0.475774:0.747037:0.475774:0.733032:0.131898:0.733032:0.006106:0.011511:0.004738:0.004505:0.011511:0.011973:0.003729:0.011511:0.003729:0.012024:0.006944:0.004738:0.004504:0.005679:0.011511:0.005456:0.004738:0.004504:0.011374:0.011990:0.010742:0.011374:0.011426:0.005456:0.004738:0.004504:0.011973:0.011990:0.003729:0.010742:0.005046:0.004738:0.004504:0.006944:0.009476:0.006944:0.006106:0.011426:0.016352:0.011990:0.006106:0.003729:0.011067
review. :@0.131898:0.761631:0.197953:0.761631:0.197953:0.747625:0.131898:0.747625:0.005386:0.011426:0.009784:0.003729:0.011426:0.014522:0.005046:0.004738
Palliative Medicine.:@0.210510:0.761631:0.389661:0.761631:0.389661:0.747625:0.210510:0.747625:0.010434:0.011990:0.003729:0.003729:0.003729:0.011990:0.006106:0.003729:0.009784:0.011426:0.017293:0.016027:0.011426:0.012024:0.003729:0.011374:0.003729:0.010742:0.011426:0.004738
 2011;25::@0.389969:0.761631:0.475747:0.761631:0.475747:0.747625:0.389969:0.747625:0.017293:0.009784:0.009784:0.009784:0.009784:0.005046:0.009784:0.009784:0.004738
553-559.:@0.131898:0.776224:0.201325:0.776224:0.201325:0.762219:0.131898:0.762219:0.009784:0.009784:0.009784:0.005987:0.009784:0.009784:0.009784:0.004738
84.:@0.084861:0.790817:0.108551:0.790817:0.108551:0.776812:0.084861:0.776812:0.009476:0.009476:0.004738
 Winter MC, Holen I,  Coleman RE. Explor-:@0.131898:0.790817:0.475805:0.790817:0.475805:0.776812:0.131898:0.776812:0.000000:0.016523:0.003421:0.010434:0.005798:0.011118:0.005148:0.006284:0.015719:0.013906:0.004738:0.006294:0.011682:0.011203:0.003421:0.011118:0.010434:0.006294:0.003866:0.004738:0.006294:0.006294:0.013906:0.011203:0.003421:0.011118:0.016044:0.011682:0.010434:0.006294:0.010382:0.009168:0.004738:0.006294:0.009168:0.008210:0.011665:0.003421:0.011203:0.005148:0.005679
ing the anti-tumour  activity  of bisphos-:@0.131898:0.805410:0.475766:0.805410:0.475766:0.791405:0.131898:0.791405:0.003421:0.010434:0.011511:0.010280:0.005798:0.010434:0.011118:0.010280:0.011682:0.010434:0.005798:0.003421:0.005679:0.005798:0.010399:0.016044:0.011203:0.010399:0.005148:0.004738:0.005532:0.011682:0.011067:0.005798:0.003421:0.009476:0.003421:0.005798:0.009168:0.004738:0.005554:0.011203:0.005371:0.010280:0.011665:0.003421:0.006636:0.011665:0.010434:0.011203:0.006636:0.005679
phonates in early breast cancer. :@0.131898:0.820004:0.410935:0.820004:0.410935:0.805998:0.131898:0.805998:0.011665:0.010434:0.011203:0.010434:0.011682:0.005798:0.011118:0.006636:0.006233:0.003421:0.010434:0.006243:0.011118:0.011682:0.005148:0.003421:0.009168:0.006243:0.011665:0.005080:0.011118:0.011682:0.006636:0.005798:0.006243:0.011067:0.011682:0.010434:0.011067:0.011118:0.003890:0.004738:0.004738
Cancer:@0.412440:0.820004:0.475795:0.820004:0.475795:0.805998:0.412440:0.805998:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148
Treatment Reviews.:@0.131898:0.834597:0.292166:0.834597:0.292166:0.820592:0.131898:0.820592:0.007286:0.005148:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004738:0.010382:0.011118:0.009476:0.003421:0.011118:0.014214:0.006636:0.004738
 2008;34:453-475.:@0.292149:0.834597:0.430489:0.834597:0.430489:0.820592:0.292149:0.820592:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
85. :@0.084861:0.849190:0.113289:0.849190:0.113289:0.835185:0.084861:0.835185:0.009476:0.009476:0.004738:0.131180
  Bayer.  BONEFOS  (sodium clodronate).:@0.131898:0.849190:0.475772:0.849235:0.475772:0.835230:0.131898:0.835185:0.004738:-0.004738:0.009818:0.011682:0.009168:0.011118:0.003898:0.004738:0.004738:0.008030:0.009818:0.014864:0.012657:0.009168:0.008296:0.014864:0.008518:0.007443:0.012777:0.006312:0.006636:0.011203:0.011716:0.003421:0.010399:0.016044:0.012777:0.011067:0.003421:0.011203:0.011716:0.005078:0.011203:0.010434:0.011682:0.005798:0.011118:0.006312:-0.231368
®:@0.273265:0.844240:0.280714:0.844240:0.280714:0.836075:0.273265:0.836075:0.007449
1-12 (Published online, 2012).:@0.131890:0.863828:0.369179:0.863828:0.369179:0.849823:0.131890:0.849823:0.009476:0.005679:0.009476:0.009476:0.004738:0.006312:0.010126:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
86.:@0.084853:0.878421:0.108543:0.878421:0.108543:0.864416:0.084853:0.864416:0.009476:0.009476:0.004738
 Wilkin, J. ALDARA™. 1-11. (FDA, published:@0.131890:0.878421:0.475756:0.878421:0.475756:0.864416:0.131890:0.864416:0.000000:0.016523:0.003421:0.003421:0.008586:0.003421:0.010434:0.004738:0.005097:0.008244:0.004738:0.005097:0.012657:0.007902:0.012726:0.012657:0.010382:0.012657:0.017104:0.004738:0.005080:0.009476:0.005679:0.009476:0.009476:0.004738:0.005097:0.006312:0.008296:0.012726:0.012657:0.004738:0.005097:0.011665:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716
online, 2002).:@0.131890:0.893015:0.240349:0.893015:0.240349:0.879009:0.131890:0.879009:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
87.:@0.084853:0.907314:0.108543:0.907314:0.108543:0.893309:0.084853:0.893309:0.009476:0.009476:0.004738
 Sagent Pharmaceuticals. MESNA injec-:@0.131890:0.907314:0.475773:0.907314:0.475773:0.893309:0.131890:0.893309:0.000000:0.008518:0.011682:0.011511:0.011118:0.010434:0.005798:0.011990:0.010126:0.010434:0.011682:0.005627:0.016044:0.011682:0.011067:0.011118:0.010399:0.005798:0.003421:0.011067:0.011682:0.003421:0.006636:0.004738:0.011990:0.015719:0.009168:0.008518:0.012657:0.012657:0.011990:0.003421:0.010434:0.003472:0.011118:0.011067:0.005679
tion 100 mg per mL. 1-2. (bdipharma, pub-:@0.131890:0.921613:0.475758:0.921613:0.475758:0.907608:0.131890:0.907608:0.005798:0.003421:0.011203:0.010434:0.003802:0.009476:0.009476:0.009476:0.003814:0.016044:0.011511:0.003804:0.011665:0.011118:0.005148:0.003804:0.016044:0.007902:0.004738:0.003802:0.009476:0.005679:0.009476:0.004738:0.003814:0.006312:0.011665:0.011716:0.003421:0.011665:0.010434:0.011682:0.005631:0.016044:0.011682:0.004738:0.003806:0.011665:0.010399:0.011665:0.005679
lished online, 2010).:@0.131890:0.935912:0.291833:0.935912:0.291833:0.921907:0.131890:0.921907:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
88.:@0.524247:0.078063:0.547937:0.078063:0.547937:0.064057:0.524247:0.064057:0.009476:0.009476:0.004738
  Japanese Gastric Cancer Association:@0.571284:0.078063:0.915150:0.078063:0.915150:0.064057:0.571284:0.064057:0.004738:-0.004738:0.008244:0.011682:0.011665:0.011682:0.010434:0.011118:0.006636:0.011118:0.015035:0.014915:0.011682:0.006636:0.005798:0.005148:0.003421:0.011067:0.015035:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.015035:0.012657:0.006636:0.006636:0.011203:0.011067:0.003421:0.011682:0.005798:0.003421:0.011203:0.010434
Gastric Cancer  (2017)  20: 1.  https://doi.:@0.571284:0.092362:0.915162:0.092362:0.915162:0.078357:0.571284:0.078357:0.014915:0.011682:0.006636:0.005798:0.005148:0.003421:0.011067:0.008467:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.003712:0.006312:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738:0.003741:0.009476:0.009476:0.004738:0.008467:0.009476:0.004738:0.004738:0.003729:0.010434:0.005798:0.005798:0.011665:0.006636:0.004738:0.007475:0.007475:0.011716:0.011203:0.003421:0.004738
org/10.1007/s10120-016-0622-4:@0.571284:0.106661:0.822547:0.106661:0.822547:0.092656:0.571284:0.092656:0.011203:0.005148:0.011511:0.007475:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475:0.006636:0.009476:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476
89.:@0.524247:0.120960:0.547937:0.120960:0.547937:0.106955:0.524247:0.106955:0.009476:0.009476:0.004738
  Petrioli R, Roviello G, Zanotti L, :@0.571284:0.120960:0.822530:0.120960:0.822530:0.106955:0.571284:0.106955:0.004738:-0.004738:0.010126:0.011118:0.005798:0.005148:0.003421:0.011203:0.003421:0.003421:0.005046:0.010382:0.004738:0.005046:0.010382:0.011203:0.009476:0.003421:0.011118:0.003421:0.003421:0.011203:0.005063:0.014915:0.004738:0.005046:0.008210:0.011682:0.010434:0.011203:0.005798:0.005798:0.003421:0.005046:0.007902:0.004738:0.004738
et al:@0.822838:0.120960:0.859903:0.120960:0.859903:0.106955:0.822838:0.106955:0.011118:0.005798:0.005046:0.011682:0.003421
. Epiru-:@0.859903:0.120960:0.915167:0.120960:0.915167:0.106955:0.859903:0.106955:0.004738:0.005046:0.009168:0.011665:0.003421:0.005148:0.010399:0.005679
bicin-based compared  with  docetaxel-:@0.571284:0.135260:0.915157:0.135260:0.915157:0.121254:0.571284:0.121254:0.011665:0.003421:0.011067:0.003421:0.010434:0.005679:0.011665:0.011682:0.006636:0.011118:0.011716:0.010314:0.011067:0.011203:0.016044:0.011665:0.011682:0.005077:0.011118:0.011716:0.004738:0.005564:0.014214:0.003421:0.005798:0.010434:0.004738:0.005564:0.011716:0.011203:0.011067:0.011118:0.005798:0.011682:0.008210:0.011118:0.003421:0.005679
based chemotherapy for advanced gas-:@0.571284:0.149559:0.915137:0.149559:0.915137:0.135554:0.571284:0.135554:0.011665:0.011682:0.006636:0.011118:0.011716:0.005012:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011104:0.005148:0.011682:0.011665:0.009168:0.005012:0.005371:0.011203:0.005148:0.005012:0.011682:0.011716:0.009476:0.011682:0.010434:0.011067:0.011118:0.011716:0.005012:0.011511:0.011682:0.006636:0.005679
tric carcinoma: a systematic review and:@0.571284:0.163858:0.915162:0.163858:0.915162:0.149853:0.571284:0.149853:0.005798:0.005148:0.003421:0.011067:0.006948:0.011067:0.011682:0.005030:0.011067:0.003421:0.010434:0.011203:0.016044:0.011682:0.004738:0.006946:0.011682:0.006953:0.006636:0.009168:0.006636:0.005798:0.011118:0.016044:0.011682:0.005798:0.003421:0.011067:0.006961:0.005077:0.011118:0.009476:0.003421:0.011118:0.014214:0.006961:0.011682:0.010434:0.011716
meta-analysis. :@0.571284:0.178157:0.694162:0.178157:0.694162:0.164152:0.571284:0.164152:0.016044:0.011118:0.005798:0.011682:0.005679:0.011682:0.010434:0.011682:0.003421:0.009168:0.006636:0.003421:0.006636:0.004738:0.004738
Critical Reviews in Oncolo-:@0.694384:0.178157:0.915167:0.178157:0.915167:0.164152:0.694384:0.164152:0.013906:0.005148:0.003421:0.005798:0.003421:0.011067:0.011682:0.003421:0.004943:0.010382:0.011118:0.009476:0.003421:0.011118:0.014214:0.006636:0.004943:0.003421:0.010434:0.004943:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.005679
gy/Hematology.:@0.571284:0.192457:0.707007:0.192457:0.707007:0.178451:0.571284:0.178451:0.011511:0.009168:0.007475:0.011682:0.011118:0.016044:0.011682:0.005798:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738
 2016;102:82-88.:@0.707007:0.192457:0.835871:0.192457:0.835871:0.178451:0.707007:0.178451:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
90.:@0.524247:0.206756:0.547937:0.206756:0.547937:0.192751:0.524247:0.192751:0.009476:0.009476:0.004738
  Lacovelli R, Pietrantonio F, Maggi C, :@0.571284:0.206756:0.872831:0.206756:0.872831:0.192751:0.571284:0.192751:0.004738:-0.004738:0.007902:0.011682:0.011067:0.011203:0.009476:0.011118:0.003421:0.003421:0.003421:0.005166:0.010382:0.004738:0.005148:0.010126:0.003421:0.011118:0.005798:0.005148:0.011682:0.010434:0.005798:0.011203:0.010434:0.003421:0.011203:0.005138:0.006205:0.004738:0.005154:0.015719:0.011682:0.011511:0.011511:0.003421:0.005154:0.013906:0.004738:0.004738
et al:@0.873245:0.206756:0.910416:0.206756:0.910416:0.192751:0.873245:0.192751:0.011118:0.005798:0.005152:0.011682:0.003421
.:@0.910416:0.206756:0.915154:0.206756:0.915154:0.192751:0.910416:0.192751:0.004738
Combination or single-agent chemother-:@0.571284:0.221055:0.915150:0.221055:0.915150:0.207050:0.571284:0.207050:0.013906:0.011203:0.016044:0.011665:0.003421:0.010434:0.011682:0.005798:0.003421:0.011203:0.010434:0.005841:0.011203:0.005148:0.005838:0.006636:0.003421:0.010434:0.011511:0.003421:0.011118:0.005679:0.011682:0.011511:0.011118:0.010434:0.005798:0.005850:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005118:0.005679
apy as adjuvant treatment of gastric can-:@0.571284:0.235355:0.915166:0.235355:0.915166:0.221349:0.571284:0.221349:0.011682:0.011665:0.009168:0.004139:0.011682:0.006636:0.004139:0.011682:0.011716:0.003472:0.010399:0.009476:0.011682:0.010434:0.005798:0.004139:0.005798:0.005075:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004126:0.011203:0.005371:0.004139:0.011511:0.011682:0.006636:0.005798:0.005148:0.003421:0.011067:0.004139:0.011067:0.011682:0.010434:0.005679
cer. :@0.571284:0.249654:0.606834:0.249654:0.606834:0.235648:0.571284:0.235648:0.011067:0.011118:0.003890:0.004738:0.004738
Critical Reviews in Oncology/Hema- :@0.609204:0.249654:0.919903:0.249654:0.919903:0.235648:0.609204:0.235648:0.013906:0.005148:0.003421:0.005798:0.003421:0.011067:0.011682:0.003421:0.007115:0.010382:0.011118:0.009476:0.003421:0.011118:0.014214:0.006636:0.007107:0.003421:0.010434:0.007105:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.007475:0.011682:0.011118:0.016044:0.011682:0.005679:0.004738
tology:@0.571284:0.263953:0.623589:0.263953:0.623589:0.249948:0.571284:0.249948:0.005798:0.011203:0.003421:0.011203:0.011511:0.009168
.2016;98:24-28.:@0.623589:0.263953:0.742978:0.263953:0.742978:0.249948:0.623589:0.249948:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
91.:@0.524247:0.278252:0.547937:0.278252:0.547937:0.264247:0.524247:0.264247:0.009476:0.009476:0.004738
  Kaboli PJ, Rahmat A, Ismail P, :@0.571284:0.278252:0.816308:0.278252:0.816308:0.264247:0.571284:0.264247:0.004738:-0.004738:0.010109:0.011682:0.011665:0.011203:0.003421:0.003421:0.004892:0.010126:0.008244:0.004738:0.004875:0.010382:0.011682:0.010434:0.016044:0.011682:0.005798:0.004892:0.012657:0.004738:0.004882:0.003866:0.006636:0.016044:0.011682:0.003421:0.003421:0.004892:0.008019:0.004738:0.004738
et al:@0.816461:0.278252:0.853364:0.278252:0.853364:0.264247:0.816461:0.264247:0.011118:0.005798:0.004883:0.011682:0.003421
. Micro-:@0.853364:0.278252:0.915162:0.278252:0.915162:0.264247:0.853364:0.264247:0.004738:0.004892:0.015719:0.003421:0.011067:0.005080:0.011203:0.005679
RNA-based therapy and breast cancer: a:@0.571284:0.292552:0.915167:0.292552:0.915167:0.278546:0.571284:0.278546:0.010382:0.012657:0.012657:0.005679:0.011665:0.011682:0.006636:0.011118:0.011716:0.004382:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004396:0.011682:0.010434:0.011716:0.004387:0.011665:0.005080:0.011118:0.011682:0.006636:0.005798:0.004387:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.004375:0.011682
comprehensive review of novel therapeu-:@0.571284:0.306851:0.915178:0.306851:0.915178:0.292846:0.571284:0.292846:0.011067:0.011203:0.016044:0.011665:0.005077:0.011118:0.010434:0.011118:0.010434:0.006636:0.003421:0.009476:0.011118:0.003848:0.005077:0.011118:0.009476:0.003421:0.011118:0.014214:0.003848:0.011203:0.005371:0.003848:0.010434:0.011203:0.009476:0.011118:0.003421:0.003848:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.011118:0.010399:0.005679
tic strategies from diagnosis to treatment.:@0.571284:0.321150:0.915171:0.321150:0.915171:0.307145:0.571284:0.307145:0.005798:0.003421:0.011067:0.005155:0.006636:0.005798:0.005148:0.011682:0.005798:0.011118:0.011511:0.003421:0.011118:0.006636:0.005152:0.005371:0.005077:0.011203:0.016044:0.005150:0.011716:0.003421:0.011682:0.011511:0.010434:0.011203:0.006636:0.003421:0.006636:0.005166:0.005798:0.011203:0.005148:0.005798:0.005075:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004738
Pharmacological Research:@0.571284:0.335449:0.825807:0.335449:0.825807:0.321444:0.571284:0.321444:0.010122:0.010430:0.012880:0.006346:0.017241:0.012880:0.012264:0.012401:0.004618:0.012401:0.012709:0.004618:0.012264:0.012880:0.004618:0.009886:0.011580:0.012315:0.007834:0.012315:0.012880:0.006346:0.012264:0.010434
. 2015;97::@0.827005:0.335449:0.915150:0.335449:0.915150:0.321444:0.827005:0.321444:0.005935:0.009886:0.010673:0.010673:0.010673:0.010673:0.005935:0.009479:0.009479:0.004738
104-121.:@0.571284:0.349749:0.638556:0.349749:0.638556:0.335743:0.571284:0.335743:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
92.:@0.524247:0.364048:0.547937:0.364048:0.547937:0.350043:0.524247:0.350043:0.009476:0.009476:0.004738
  Senkus E, Kyriakides S, Ohno S, :@0.571284:0.364048:0.835511:0.364048:0.835511:0.350043:0.571284:0.350043:0.004738:-0.004738:0.008518:0.011118:0.010434:0.008586:0.010399:0.006636:0.007081:0.009168:0.004738:0.007088:0.010109:0.009168:0.005148:0.003421:0.011682:0.008586:0.003421:0.011716:0.011118:0.006636:0.007098:0.008518:0.004738:0.007086:0.014864:0.010434:0.010434:0.011203:0.007085:0.008518:0.004738:0.004738
et al:@0.837856:0.364048:0.876960:0.364048:0.876960:0.350043:0.837856:0.350043:0.011118:0.005798:0.007085:0.011682:0.003421
., on:@0.876960:0.364048:0.915155:0.364048:0.915155:0.350043:0.876960:0.350043:0.004738:0.004738:0.007083:0.011203:0.010434
behalf of  the  ESMO Guidelines Commit-:@0.571284:0.378347:0.915176:0.378347:0.915176:0.364342:0.571284:0.364342:0.011665:0.011118:0.010434:0.011682:0.003421:0.005371:0.007868:0.011203:0.005371:0.004738:0.003120:0.005798:0.010434:0.011118:0.004738:0.003115:0.009168:0.008518:0.015719:0.014864:0.007868:0.014915:0.010399:0.003421:0.011716:0.011118:0.003421:0.003421:0.010434:0.011118:0.006636:0.007868:0.013906:0.011203:0.016044:0.016044:0.003421:0.005798:0.005679
tee; Primary breast cancer: ESMO Clinical:@0.571284:0.392646:0.915155:0.392646:0.915155:0.378641:0.571284:0.378641:0.005798:0.011118:0.011118:0.004738:0.004810:0.010126:0.005148:0.003421:0.016044:0.011682:0.005148:0.009168:0.004823:0.011665:0.005080:0.011118:0.011682:0.006636:0.005798:0.004823:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.004808:0.009168:0.008518:0.015719:0.014864:0.004823:0.013906:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421
Practice  Guidelines  for  diagnosis, treat-:@0.571284:0.406946:0.915160:0.406946:0.915160:0.392940:0.571284:0.392940:0.010126:0.005148:0.011682:0.011067:0.005798:0.003421:0.011067:0.011118:0.004738:0.005148:0.014915:0.010399:0.003421:0.011716:0.011118:0.003421:0.003431:0.010434:0.011118:0.006636:0.004738:0.005155:0.005371:0.011203:0.005148:0.004738:0.005147:0.011716:0.003421:0.011682:0.011511:0.010434:0.011203:0.006636:0.003421:0.006636:0.004738:0.009903:0.005798:0.005075:0.011118:0.011682:0.005798:0.005679
ment and follow-up, :@0.571284:0.421245:0.744928:0.421245:0.744928:0.407240:0.571284:0.407240:0.016044:0.011118:0.010434:0.005798:0.005174:0.011682:0.010434:0.011716:0.005183:0.005371:0.011203:0.003421:0.003421:0.011203:0.014214:0.005679:0.010399:0.011665:0.004746:0.122006
Annals of Oncology.:@0.745372:0.421245:0.915184:0.421245:0.915184:0.407240:0.745372:0.407240:0.012657:0.010434:0.010434:0.011682:0.003421:0.006636:0.005183:0.011203:0.005371:0.005183:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738
2015;26(5):v8-v30,  https://doi.org/10.1093/:@0.571284:0.435544:0.915150:0.435544:0.915150:0.421539:0.571284:0.421539:0.009305:0.009305:0.009305:0.009305:0.004567:0.009305:0.009305:0.006140:0.009305:0.006140:0.004567:0.009305:0.009305:0.005508:0.009305:0.009305:0.009305:0.004567:0.004738:0.004396:0.010263:0.005627:0.005627:0.011494:0.006465:0.004567:0.007304:0.007304:0.011545:0.011032:0.003250:0.004567:0.011032:0.004994:0.011340:0.007304:0.009305:0.009305:0.004567:0.009305:0.009305:0.009305:0.009305:-0.066278
annonc/mdv298:@0.571284:0.449843:0.709676:0.449843:0.709676:0.435838:0.571284:0.435838:0.011682:0.010434:0.010434:0.011203:0.010434:0.011067:0.007475:0.016044:0.011716:0.009476:0.009476:0.009476:0.009476
93.:@0.524247:0.464143:0.547944:0.464143:0.547944:0.450137:0.524247:0.450137:0.009479:0.009479:0.004738
  Yamamoto-Ibusuki M, Arnedos M, André F.:@0.571284:0.464143:0.915178:0.464143:0.915178:0.450137:0.571284:0.450137:0.004738:-0.004738:0.008193:0.011340:0.015702:0.011340:0.015702:0.010861:0.005456:0.010861:0.005337:0.003523:0.011323:0.010057:0.006294:0.010057:0.008244:0.003079:0.005882:0.015377:0.004396:0.005882:0.012315:0.005162:0.010092:0.010776:0.011374:0.010861:0.006284:0.005884:0.015377:0.004396:0.005884:0.012315:0.010092:0.011374:0.004806:0.010776:0.005882:0.006597:0.004738
Targeted therapies for ER+/HER2- metastat-:@0.571284:0.478442:0.915181:0.478442:0.915181:0.464437:0.571284:0.464437:0.006055:0.011340:0.004820:0.011169:0.010776:0.005456:0.010776:0.011374:0.004823:0.005456:0.010092:0.010776:0.004806:0.011340:0.011323:0.003079:0.010776:0.006294:0.004823:0.005029:0.010861:0.004806:0.004823:0.008826:0.010040:0.010023:0.007133:0.011340:0.008826:0.010040:0.009134:0.005337:0.004823:0.015702:0.010776:0.005456:0.011340:0.006294:0.005456:0.011340:0.005456:0.005679
ic:@0.571284:0.492741:0.585087:0.492741:0.585087:0.478736:0.571284:0.478736:0.003079:0.010724
breast:@0.610111:0.492741:0.660037:0.492741:0.660037:0.478736:0.610111:0.478736:0.011323:0.004736:0.010776:0.011340:0.006294:0.005456
cancer.:@0.685061:0.492741:0.746662:0.492741:0.746662:0.478736:0.685061:0.478736:0.010724:0.011340:0.010092:0.010724:0.010776:0.003549:0.004396
BMC:@0.771686:0.492741:0.810102:0.492741:0.810102:0.478736:0.771686:0.478736:0.009476:0.015377:0.013564
Medicine:@0.835126:0.492741:0.910744:0.492741:0.910744:0.478736:0.835126:0.478736:0.015377:0.010776:0.011374:0.003079:0.010724:0.003079:0.010092:0.011118
.:@0.910402:0.492741:0.915140:0.492741:0.915140:0.478736:0.910402:0.478736:0.004738
2015;13:137 DOI 10.1186/s12916-015-0369-5:@0.571284:0.507040:0.909215:0.507040:0.909215:0.493035:0.571284:0.493035:0.009134:0.009134:0.009134:0.009134:0.004396:0.009134:0.009134:0.004396:0.009134:0.009134:0.009134:0.004396:0.012384:0.014522:0.003523:0.004396:0.009134:0.009134:0.004396:0.009134:0.009134:0.009134:0.009134:0.007133:0.006294:0.009134:0.009134:0.009134:0.009134:0.009134:0.005337:0.009134:0.009134:0.009134:0.005337:0.009134:0.009134:0.009134:0.009134:0.005337:0.009476
94.:@0.524247:0.521340:0.547937:0.521340:0.547937:0.507334:0.524247:0.507334:0.009476:0.009476:0.004738
  Hu X-C,  Zhang  J,  Xu  B-H, :@0.571284:0.521340:0.789519:0.521340:0.789519:0.507334:0.571284:0.507334:0.004738:-0.004738:0.011682:0.010399:0.007748:0.010417:0.005679:0.013906:0.004738:0.004738:0.002993:0.008210:0.010434:0.011682:0.010434:0.011511:0.004738:0.002998:0.008244:0.004738:0.004738:0.003000:0.010417:0.010399:0.004738:0.002998:0.009818:0.005679:0.011682:0.004738:0.004738
et  al.:@0.792529:0.521340:0.837024:0.521340:0.837024:0.507334:0.792529:0.507334:0.011118:0.005798:0.004738:0.003000:0.011682:0.003421:0.004738
  Cisplatin:@0.837024:0.521340:0.915148:0.521340:0.915148:0.507334:0.837024:0.507334:0.004738:0.003002:0.013906:0.003421:0.006636:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434
plus gemcitabine  versus paclitaxel  plus:@0.571284:0.535639:0.915148:0.535639:0.915148:0.521634:0.571284:0.521634:0.011665:0.003421:0.010399:0.006636:0.010365:0.011511:0.011118:0.016044:0.011067:0.003421:0.005798:0.011682:0.011665:0.003421:0.010434:0.011118:0.004738:0.005617:0.009476:0.011118:0.005148:0.006636:0.010399:0.006636:0.010365:0.011665:0.011682:0.011067:0.003421:0.003421:0.005798:0.011682:0.008210:0.011118:0.003421:0.004738:0.005619:0.011665:0.003421:0.010399:0.006636
gemcitabine as first-line therapy for meta-:@0.571284:0.549938:0.915164:0.549938:0.915164:0.535933:0.571284:0.535933:0.011511:0.011118:0.016044:0.011067:0.003421:0.005798:0.011682:0.011665:0.003421:0.010434:0.011118:0.004249:0.011682:0.006636:0.004254:0.004165:0.004165:0.005148:0.006636:0.005798:0.005679:0.003421:0.003421:0.010434:0.011118:0.004249:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004245:0.005371:0.011203:0.005148:0.004244:0.016044:0.011118:0.005798:0.011682:0.005679
static triple-negative breast cancer (CBC-:@0.571284:0.564237:0.915159:0.564237:0.915159:0.550232:0.571284:0.550232:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.004139:0.005798:0.005148:0.003421:0.011665:0.003421:0.011118:0.005679:0.010434:0.011118:0.011511:0.011682:0.005798:0.003421:0.009476:0.011118:0.004139:0.011665:0.005080:0.011118:0.011682:0.006636:0.005798:0.004139:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004131:0.006312:0.013906:0.009818:0.013906:0.005679
SG006): a randomised, open-label, multi-:@0.571284:0.578537:0.915138:0.578537:0.915138:0.564531:0.571284:0.564531:0.008518:0.014915:0.009476:0.009476:0.009476:0.006312:0.004738:0.006137:0.011682:0.006123:0.005148:0.011682:0.010434:0.011716:0.011195:0.016044:0.003421:0.006636:0.011118:0.011716:0.004738:0.006123:0.011203:0.011665:0.011118:0.010434:0.005679:0.003421:0.011682:0.011665:0.011118:0.003421:0.004738:0.006123:0.016044:0.010399:0.003421:0.005798:0.003421:0.005679
centre, phase 3 trial. :@0.571284:0.592836:0.747878:0.592836:0.747878:0.578831:0.571284:0.578831:0.011067:0.011118:0.010434:0.005798:0.005071:0.011118:0.004738:0.005764:0.011665:0.010434:0.011682:0.006636:0.011118:0.005764:0.009476:0.005764:0.005798:0.005148:0.003421:0.011682:0.003421:0.004738:0.004738
The Lancet Oncolo- :@0.748904:0.592836:0.919880:0.592836:0.919880:0.578831:0.748904:0.578831:0.007286:0.010434:0.011118:0.005764:0.007902:0.011682:0.010434:0.011067:0.011118:0.005798:0.005764:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.005679:0.004738
gy:@0.571284:0.607135:0.591963:0.607135:0.591963:0.593130:0.571284:0.593130:0.011511:0.009168
. 2015;16(4):436-446.:@0.591963:0.607135:0.757140:0.607135:0.757140:0.593130:0.591963:0.593130:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
95.:@0.524247:0.621434:0.547937:0.621434:0.547937:0.607429:0.524247:0.607429:0.009476:0.009476:0.004738
  Kreitzburg KM, Landen CN, Gamblin T, :@0.571284:0.621434:0.896580:0.621434:0.896580:0.607429:0.571284:0.607429:0.004738:-0.004738:0.010109:0.005080:0.011118:0.003421:0.005798:0.007269:0.011665:0.010399:0.005159:0.011511:0.006404:0.010109:0.015719:0.004738:0.006400:0.007902:0.011682:0.010434:0.011716:0.011118:0.010434:0.006400:0.013906:0.012657:0.004738:0.006400:0.014915:0.011682:0.016044:0.011665:0.003421:0.003421:0.010434:0.006414:0.005537:0.004738:0.004738
et:@0.898256:0.621434:0.915172:0.621434:0.915172:0.607429:0.898256:0.607429:0.011118:0.005798
al.:@0.571284:0.635734:0.591125:0.635734:0.591125:0.621728:0.571284:0.621728:0.011682:0.003421:0.004738
 Combination of FTY720 and tamoxifen:@0.591125:0.635734:0.915162:0.635734:0.915162:0.621728:0.591125:0.621728:0.005402:0.013906:0.011203:0.016044:0.011665:0.003421:0.010434:0.011682:0.005798:0.003421:0.011203:0.010434:0.005400:0.011203:0.005371:0.005396:0.008296:0.007286:0.010126:0.009476:0.009476:0.009476:0.005403:0.011682:0.010434:0.011716:0.005402:0.005798:0.011682:0.016044:0.011203:0.008210:0.003421:0.005371:0.011118:0.010434
inhibits drug-resistant ovarian cancer cell:@0.571284:0.650033:0.915145:0.650033:0.915145:0.636028:0.571284:0.636028:0.003421:0.010434:0.010434:0.003421:0.011665:0.003421:0.005798:0.006636:0.006260:0.011716:0.005148:0.010399:0.011511:0.005679:0.005070:0.011118:0.006636:0.003421:0.006636:0.005798:0.011682:0.010434:0.005798:0.006243:0.011203:0.009476:0.011682:0.005148:0.003421:0.011682:0.010434:0.006248:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.006243:0.011067:0.011118:0.003421:0.003421
proliferation [abstract]. In: Proceedings of:@0.571284:0.664332:0.915159:0.664332:0.915159:0.650327:0.571284:0.650327:0.011665:0.005080:0.011203:0.003421:0.003421:0.005371:0.011118:0.005148:0.011682:0.005798:0.003421:0.011203:0.010434:0.004911:0.006004:0.011682:0.011665:0.006636:0.005798:0.005148:0.011682:0.011067:0.005798:0.006004:0.004738:0.004907:0.003866:0.010434:0.004738:0.004914:0.010126:0.005073:0.011203:0.011067:0.011118:0.011118:0.011716:0.003421:0.010434:0.011511:0.006636:0.004919:0.011203:0.005371
the American Association for Cancer Re-:@0.571284:0.678632:0.915184:0.678632:0.915184:0.664626:0.571284:0.664626:0.005798:0.010434:0.011118:0.005713:0.012657:0.016044:0.011118:0.005148:0.003421:0.011067:0.011682:0.010434:0.005713:0.012657:0.006636:0.006636:0.011203:0.011067:0.003421:0.011682:0.005798:0.003421:0.011203:0.010434:0.005713:0.005371:0.011203:0.005148:0.005713:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.005713:0.010382:0.011118:0.005679
search  Annual  Meeting  2017; 2017 Apr:@0.571284:0.692931:0.915150:0.692931:0.915150:0.678925:0.571284:0.678925:0.006636:0.011118:0.011682:0.005030:0.011067:0.010434:0.004738:0.005208:0.012657:0.010434:0.010434:0.010399:0.011682:0.003421:0.004738:0.005205:0.015719:0.011118:0.011118:0.005798:0.003421:0.010434:0.011511:0.004738:0.005201:0.009476:0.009476:0.009476:0.009476:0.004738:0.009955:0.009476:0.009476:0.009476:0.009476:0.009955:0.012657:0.011665:0.005148
1-5; Washington, DC. Philadelphia (PA)::@0.571284:0.707230:0.915167:0.707230:0.915167:0.693225:0.571284:0.693225:0.009476:0.005679:0.009476:0.004738:0.009972:0.015567:0.011682:0.006636:0.010434:0.003421:0.010434:0.011511:0.005798:0.011203:0.010434:0.004724:0.009972:0.012726:0.013906:0.004738:0.009972:0.010126:0.010434:0.003421:0.003421:0.011682:0.011716:0.011118:0.003421:0.011665:0.010434:0.003421:0.011682:0.009972:0.006312:0.008855:0.012657:0.006312:0.004738
AACR;  Cancer  Res  2017;77(13):Abstract:@0.571284:0.721529:0.915157:0.721529:0.915157:0.707524:0.571284:0.707524:0.012657:0.012657:0.013906:0.010382:0.004738:0.004738:0.005143:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.005148:0.010382:0.011118:0.006636:0.004738:0.005155:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.012679:0.011665:0.006636:0.005798:0.005148:0.011682:0.011067:0.005798
nr 4115.:@0.571284:0.735829:0.634245:0.735829:0.634245:0.721823:0.571284:0.721823:0.010434:0.005148:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
96.:@0.524247:0.750128:0.547937:0.750128:0.547937:0.736123:0.524247:0.736123:0.009476:0.009476:0.004738
  Kummar S, Oza AM, Fleming GF, :@0.571284:0.750128:0.863888:0.750128:0.863888:0.736123:0.571284:0.736123:0.004738:-0.004738:0.010109:0.010399:0.016044:0.016044:0.011682:0.005148:0.009630:0.008518:0.004738:0.009630:0.014864:0.007269:0.011682:0.009630:0.012657:0.015719:0.004738:0.009630:0.008296:0.003421:0.011118:0.016044:0.003421:0.010434:0.011511:0.009630:0.014915:0.006209:0.004738:0.004738
et al:@0.868780:0.750128:0.910429:0.750128:0.910429:0.736123:0.868780:0.736123:0.011118:0.005798:0.009630:0.011682:0.003421
.:@0.910429:0.750128:0.915167:0.750128:0.915167:0.736123:0.910429:0.736123:0.004738
Randomized trial of oral cyclophospha-:@0.571284:0.764427:0.915150:0.764427:0.915150:0.750422:0.571284:0.750422:0.010382:0.011682:0.010434:0.011716:0.011203:0.016044:0.003421:0.007269:0.011118:0.011716:0.009014:0.005798:0.005148:0.003421:0.011682:0.003421:0.009014:0.011203:0.005371:0.009014:0.011203:0.005148:0.011682:0.003421:0.009014:0.011067:0.009168:0.011067:0.003421:0.011203:0.011665:0.010434:0.011203:0.006636:0.011665:0.010434:0.011682:0.005679
mide and veliparib in high-grade  serous:@0.571284:0.778726:0.915169:0.778726:0.915169:0.764721:0.571284:0.764721:0.016044:0.003421:0.011716:0.011118:0.007834:0.011682:0.010434:0.011716:0.007834:0.009476:0.011118:0.003421:0.003421:0.011665:0.011682:0.005148:0.003421:0.011665:0.007834:0.003421:0.010434:0.007834:0.010434:0.003421:0.011511:0.010434:0.005679:0.011511:0.005148:0.011682:0.011716:0.011118:0.004738:0.003080:0.006636:0.011118:0.005080:0.011203:0.010399:0.006636
ovarian, primary peritoneal,  or  fallopian:@0.571284:0.793026:0.915159:0.793026:0.915159:0.779020:0.571284:0.779020:0.011203:0.009476:0.011682:0.005148:0.003421:0.011682:0.010434:0.004738:0.008860:0.011665:0.005148:0.003421:0.016044:0.011682:0.005148:0.009168:0.008860:0.011665:0.011118:0.005148:0.003421:0.005798:0.011203:0.010434:0.011118:0.011682:0.003421:0.004738:0.004738:0.004110:0.011203:0.005148:0.004738:0.004108:0.005371:0.011682:0.003421:0.003421:0.011203:0.011665:0.003421:0.011682:0.010434
tube  cancers,  or :@0.571284:0.807325:0.723752:0.807325:0.723752:0.793320:0.571284:0.793320:0.005798:0.010399:0.011665:0.011118:0.004738:0.005516:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.006636:0.004738:0.004738:0.005511:0.011203:0.005154:-0.418389
BRCA:@0.729260:0.807325:0.776023:0.807325:0.776023:0.793320:0.729260:0.793320:0.009818:0.010382:0.013906:0.012657
-mutant  ovarian:@0.776023:0.807325:0.915155:0.807325:0.915155:0.793320:0.776023:0.793320:0.005679:0.016044:0.010399:0.005798:0.011682:0.010434:0.005798:0.004738:0.005513:0.011203:0.009476:0.011682:0.005148:0.003421:0.011682:0.010434
cancer. :@0.571284:0.821624:0.640009:0.821624:0.640009:0.807619:0.571284:0.807619:0.011067:0.011682:0.010434:0.011067:0.011118:0.003890:0.004731:-0.355445
Clinical cancer research: an offi:@0.641036:0.821624:0.909490:0.821624:0.909490:0.807619:0.641036:0.807619:0.013906:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.005781:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.005757:0.005148:0.011118:0.006636:0.011118:0.011682:0.005148:0.011067:0.010434:0.004738:0.005756:0.011682:0.010434:0.005764:0.011203:0.005371:0.004165:-0.625499
-:@0.909472:0.821624:0.915150:0.821624:0.915150:0.807619:0.909472:0.807619:0.005679
cial journal of the American  Associa- :@0.571284:0.835923:0.919897:0.835923:0.919897:0.821918:0.571284:0.821918:0.011067:0.003421:0.011682:0.003421:0.012811:0.003472:0.011203:0.010399:0.005148:0.010434:0.011682:0.003421:0.012811:0.011203:0.005371:0.012811:0.005798:0.010434:0.011118:0.012811:0.012657:0.016044:0.011118:0.005148:0.003421:0.011067:0.011682:0.010434:0.004738:0.008065:0.012657:0.006636:0.006636:0.011203:0.011067:0.003421:0.011682:0.005679:0.004738
tion for  Cancer Research:@0.571284:0.850223:0.807690:0.850223:0.807690:0.836217:0.571284:0.836217:0.005798:0.003421:0.011203:0.010434:0.014299:0.005371:0.011203:0.005148:0.004738:0.009551:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.014299:0.010382:0.011118:0.006636:0.011118:0.011682:0.005148:0.011067:0.010434
. 2015;21(7)::@0.807690:0.850223:0.915157:0.850223:0.915157:0.836217:0.807690:0.836217:0.004738:0.014299:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738
1574-1582.:@0.571284:0.864522:0.657507:0.864522:0.657507:0.850517:0.571284:0.850517:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
97.:@0.524247:0.878821:0.547944:0.878821:0.547944:0.864816:0.524247:0.864816:0.009479:0.009479:0.004738
  Kumar A, Nhu L, Santos JRN, :@0.571284:0.878821:0.802296:0.878821:0.802296:0.864816:0.571284:0.864816:0.004738:-0.004738:0.009767:0.010057:0.015702:0.011340:0.004806:0.005319:0.012315:0.004396:0.005319:0.012315:0.010092:0.010057:0.005319:0.007560:0.004396:0.005319:0.008176:0.011340:0.010092:0.005456:0.010861:0.006294:0.005319:0.007902:0.010040:0.012315:0.004396:0.004738
et al.:@0.802877:0.878821:0.843586:0.878821:0.843586:0.864816:0.802877:0.864816:0.010776:0.005456:0.005319:0.011340:0.003079:0.004738
 Chemo-:@0.843243:0.878821:0.915236:0.878821:0.915236:0.864816:0.843243:0.864816:0.005319:0.013564:0.010092:0.010776:0.015702:0.010861:0.005679
therapy is of value in second line and be-:@0.571284:0.893120:0.915150:0.893120:0.915150:0.879115:0.571284:0.879115:0.005456:0.010092:0.010776:0.004806:0.011340:0.011323:0.008826:0.006337:0.003079:0.006294:0.006337:0.010861:0.005029:0.006337:0.009134:0.011340:0.003079:0.010057:0.010776:0.006337:0.003079:0.010092:0.006337:0.006294:0.010776:0.010724:0.010861:0.010092:0.011374:0.006337:0.003079:0.003079:0.010092:0.010776:0.006337:0.011340:0.010092:0.011374:0.006337:0.011323:0.010776:0.005679
yond, relapsed high-grade, serous epitheli-:@0.571284:0.907420:0.915160:0.907420:0.915160:0.893414:0.571284:0.893414:0.008826:0.010861:0.010092:0.011374:0.004396:0.005662:0.004734:0.010776:0.003079:0.011340:0.011323:0.006294:0.010776:0.011374:0.005662:0.010092:0.003079:0.011169:0.010092:0.005337:0.011169:0.004806:0.011340:0.011374:0.010776:0.004396:0.005662:0.006294:0.010776:0.004734:0.010861:0.010057:0.006294:0.005662:0.010776:0.011323:0.003079:0.005456:0.010092:0.010776:0.003079:0.003079:0.005679
al ovarian cancer: an analysis of outcomes:@0.571284:0.921719:0.915150:0.921719:0.915150:0.907714:0.571284:0.907714:0.011340:0.003079:0.004533:0.010861:0.009134:0.011340:0.004806:0.003079:0.011340:0.010092:0.004533:0.010724:0.011340:0.010092:0.010724:0.010776:0.004806:0.004396:0.004533:0.011340:0.010092:0.004533:0.011340:0.010092:0.011340:0.003079:0.008826:0.006294:0.003079:0.006294:0.004533:0.010861:0.005029:0.004533:0.010861:0.010057:0.005456:0.010724:0.010861:0.015702:0.010776:0.006636
obtained with oral etoposide. :@0.571284:0.936018:0.830073:0.936018:0.830073:0.922013:0.571284:0.922013:0.010861:0.011323:0.005456:0.011340:0.003079:0.010092:0.010776:0.011374:0.010656:0.013872:0.003079:0.005456:0.010092:0.010656:0.010861:0.004806:0.011340:0.003079:0.010656:0.010776:0.005456:0.010861:0.011323:0.010861:0.006294:0.003079:0.011374:0.010776:0.004396:-0.711900
American:@0.835991:0.936018:0.915167:0.936018:0.915167:0.922013:0.835991:0.922013:0.012315:0.015702:0.010776:0.004806:0.003079:0.010724:0.011340:0.010434
References:@0.786077:0.038601:0.914549:0.038601:0.914549:0.019343:0.786077:0.019343:0.014276:0.015287:0.007385:0.015287:0.006976:0.015287:0.014346:0.015216:0.015287:0.009125